However, further studies did not confirm the favorable outcome of NPM1-mutated AML patients with FLT3-ITD low allelic ratio, at least when treated with intensive chemotherapy alone [30,31,32], while the addition of midostaurin significantly improved outcomes also in this latter genotype [33]. This evidence concerns the gene NPM1 and acute myeloid leukemia.